ダウンロード数: 183

このアイテムのファイル:
ファイル 記述 サイズフォーマット 
38_613.pdf461.67 kBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド言語
dc.contributor.author藤田, 民夫ja
dc.contributor.author大島, 伸一ja
dc.contributor.author浅野, 晴好ja
dc.contributor.author小野, 佳成ja
dc.contributor.author絹川, 常郎ja
dc.contributor.author加藤, 範夫ja
dc.contributor.author平林, 聡ja
dc.contributor.alternativeFujita, Tamioen
dc.contributor.alternativeOhshima, Shinichien
dc.contributor.alternativeAsano, Haruyoshien
dc.contributor.alternativeOno, Yoshinarien
dc.contributor.alternativeKinukawa, Tsuneoen
dc.contributor.alternativeKato, Norioen
dc.contributor.alternativeHirabayashi, Satoshien
dc.date.accessioned2010-06-01T02:43:30Z-
dc.date.available2010-06-01T02:43:30Z-
dc.date.issued1992-05-
dc.identifier.issn0018-1994-
dc.identifier.urihttp://hdl.handle.net/2433/117541-
dc.description.abstract55~83歳の前立腺肥大症患者35例において, 本剤1.5 mg/日投与群と3.0 mg/日投与群とを比較したが, 主治医による自覚症状改善度, 他覚所見改善度, 全般改善度, 概括安全度, 有用度の判定, 並びに判定委員会による薬剤効果の判定において, 両群間に統計学的有意差が認められず, 初回投与量は1.5 mg/日が至適と考えられた.12週間投与した症例で特徴的な副作用はなかった.主治医判定における12週後の改善度は, 4週後の改善度に比べ低かった.しかし判定委員会判定で自覚症状の重症度及び他覚所見は, 12週後では4週に比べ, より改善が認められたja
dc.description.abstractThirty-five patients with prostatic hyperplasia were entered into a randomized controlled study using bunazosin hydrochloride(alpha 1-adrenergic blocker). Eighteen patients were allocated to be treated with an initial dose of 1.5 mg/day (group 1) and 17 patients received an initial dose of 3.0 mg/day (group 2). Subjective symptoms and parameters of urodynamic studies were evaluated after 4 weeks and 12 weeks. There were 5 withdrawals or exclusions within 4 weeks and 6 within 12 weeks. Therefore, 15 patients in group 1 and 15 patients in group 2 were eligible for evaluation at 4 weeks, 12 patients in group 1 and 11 patients in group 2 were eligible for evaluation at 12 weeks. The rates of the improvement in subjective symptoms such as retarded urination, protracted urination, weakened urinary stream, abdominal straining on voiding, and sense of residual urine were 40%, 25% in group 1 and 46.7%, 36.4% in group 2, at 4 weeks and at 12 weeks, respectively. The rate of improvement in objective parameters of the urodynamic study such as voiding volume, residual volume, maximum flow rate and average flow rate were 26.7%, 16.7% in group 1 and 26.7%, 20.0% in group 2, at 4 weeks and at 12 weeks, respectively. Thus, these improvements were not correlated with the dosage of drug. Adverse effects such as diarrhea, mild headache, palpitation and gastric disturbance were observed in 2 patients in group 1, and 3 patients in group 2. In the 24 patients treated with the drug over 12 weeks, there were no specific adverse effects due to prolonged administration. These findings showed that bunazosin hydrochloride is beneficial for the treatment of prostatic hyperplasia, and could be safety administered for a prolonged period of time up to 12 weeks.en
dc.format.mimetypeapplication/pdf-
dc.language.isojpn-
dc.publisher泌尿器科紀要刊行会ja
dc.subjectBunazosin hydrochlorideen
dc.subjectaradrenergic blockeren
dc.subjectProstatic hyperplasiaen
dc.subject.ndc494.9-
dc.title前立腺肥大症に対するアルファ遮断剤(塩酸ブナゾシン)の臨床効果ja
dc.title.alternativeThe evaluation of the effects of bunazosin hydrochloride in the treatment of prostatic hyperplasiaen
dc.typedepartmental bulletin paper-
dc.type.niitypeDepartmental Bulletin Paper-
dc.identifier.ncidAN00208315-
dc.identifier.jtitle泌尿器科紀要ja
dc.identifier.volume38-
dc.identifier.issue5-
dc.identifier.spage613-
dc.identifier.epage621-
dc.textversionpublisher-
dc.sortkey21-
dc.address名古屋記念病院泌尿器科ja
dc.address社会保険中京病院泌尿器科ja
dc.address愛知県済生会病院泌尿器科ja
dc.address小牧市民病院泌尿器科ja
dc.address市立岡崎病院泌尿器科ja
dc.address静岡済生会病院泌尿器科ja
dc.address成田記念病院泌尿器科ja
dc.address.alternativethe Department of Urology, Nagoya Memorial Hospitalen
dc.address.alternativethe Department of Urology, Shakaihoken Chukyou Hospitalen
dc.address.alternativethe Department of Urology, Aichiken Saiseikai Hospitalen
dc.address.alternativethe Department of Urology, Komaki Shimin Hospitalen
dc.address.alternativethe Department of Urology, Okazaki Shiritsu Hospitalen
dc.address.alternativethe Department of Urology, Shizuoka Saiseikai Hospitalen
dc.address.alternativethe Department of Urology, Narita Memorial Hospitalen
dc.identifier.pmid1376962-
dcterms.accessRightsopen access-
dc.identifier.pissn0018-1994-
dc.identifier.jtitle-alternativeActa urologica Japonicala
dc.identifier.jtitle-alternativeHinyokika Kiyoen
出現コレクション:Vol.38 No.5

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。